<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Atomoxetine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Atomoxetine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Atomoxetine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11042" href="/d/html/11042.html" rel="external">see "Atomoxetine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13048" href="/d/html/13048.html" rel="external">see "Atomoxetine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708625"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Suicidal ideation in children and adolescents:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine increased the risk of suicidal ideation in short-term studies in children or adolescents with attention deficit hyperactivity disorder (ADHD). Anyone considering the use of atomoxetine in a child or adolescent must balance this risk with the clinical need. Comorbidities occurring with ADHD may be associated with an increase in the risk of suicidal ideation and/or behavior. Closely monitor patients who are started on therapy for suicidality (suicidal thinking and behavior), clinical worsening, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication with the prescribing health care provider. Atomoxetine is approved for ADHD in pediatric and adult patients. Atomoxetine is not approved for major depressive disorder (MDD).</p>
<p style="text-indent:-2em;margin-left:2em;">Pooled analyses of short-term (6- to 18-week), placebo-controlled trials of atomoxetine in children and adolescents (12 trials involving more than 2,200 patients, including 11 trials in ADHD and 1 trial in enuresis) have revealed a greater risk of suicidal ideation early during treatment in those receiving atomoxetine compared with placebo. The average risk of suicidal ideation in patients receiving atomoxetine was 0.4% compared with none in placebo-treated patients. No suicides occurred in these trials.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F137799"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Strattera</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866005"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Atomoxetine;</li>
<li>AURO-Atomoxetine;</li>
<li>DOM-Atomoxetine [DSC];</li>
<li>JAMP-Atomoxetine;</li>
<li>PMS-Atomoxetine;</li>
<li>RIVA-Atomoxetine;</li>
<li>SANDOZ Atomoxetine;</li>
<li>Strattera;</li>
<li>TEVA-Atomoxetine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F137817"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Norepinephrine Reuptake Inhibitor, Selective</li></ul></div>
<div class="block doa drugH1Div" id="F137801"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc8a7e32-2b4e-402d-ae6a-0c132cdad29a">Attention-deficit/hyperactivity disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder (ADHD):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Generally reserved for patients with a history of substance use disorder or those who cannot tolerate or do not have a sufficient response to preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brent.1','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brent.1','lexi-content-ref-NICE.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 40 mg once daily. Increase after ≥3 days to 80 mg/day; may administer as a single daily dose in the morning or as 2 evenly divided doses in the morning and late afternoon/early evening. After an additional 2 to 4 weeks, may increase based on response and tolerability to 100 mg/day in 1 or 2 divided doses. Maximum: 100 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage adjustment based on CYP2D6 metabolizer status:</b>
<i>Patients known to be CYP2D6 poor metabolizers</i>: Initial: 40 mg/day; if tolerating therapy but inadequate response, may increase after ≥4 weeks to 80 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="69afded6-a0bc-40b9-a7fc-67cc54ec6a78">Orthostatic hypotension, neurogenic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Orthostatic hypotension, neurogenic (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be useful for management of symptoms unresponsive to volume repletion in patients with normal or elevated serum norepinephrine levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Palma.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Palma.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 10 mg twice daily; may increase to 18 mg twice daily, if needed, based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31996627','lexi-content-ref-Palma.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31996627','lexi-content-ref-Palma.2022'])">Ref</a></span>). <b>Note:</b> Although short-term trials demonstrated efficacy of a fixed dose of 18 mg once daily, an initial dose of 10 mg twice daily, adjusted if needed, may be preferred for individualizing therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31856425','lexi-content-ref-22311903','lexi-content-ref-30571543','lexi-content-ref-25185131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31856425','lexi-content-ref-22311903','lexi-content-ref-30571543','lexi-content-ref-25185131'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991720"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50989043"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): No dosage adjustment provided in manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (Child-Pugh class B): Reduce dose to 50% of normal dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Reduce dose to 25% of normal dose.</p></div>
<div class="block doe drugH1Div" id="F137802"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Use has not been evaluated in older adults.</p></div>
<div class="block dop drugH1Div" id="F137809"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13048" href="/d/html/13048.html" rel="external">see "Atomoxetine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc8a7e32-2b4e-402d-ae6a-0c132cdad29a">Attention-deficit/hyperactivity disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder:</b>
<b> Note:</b> Use is suggested in patients who are intolerant of or lack a response to stimulants; an adequate stimulant trial of at least 6 weeks is suggested prior to initiating atomoxetine; not typically used first-line (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31570648','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31570648','lexi-content-ref-NICE.1'])">Ref</a></span>). Atomoxetine may be an optimal selection for patients with tics or Tourette syndrome comorbidity, or if stimulant diversion or misuse is a concern (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NICE.1','lexi-content-ref-31061208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NICE.1','lexi-content-ref-31061208'])">Ref</a></span>). As a nonstimulant drug, atomoxetine may take longer to provide therapeutic effect than stimulant therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NICE.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight ≤70 kg: Oral: Initial: ~0.5 mg/kg/day; increase after a minimum of 3 days to ~1.2 mg/kg/day; may administer either once daily in the morning or in 2 evenly divided doses in the morning and late afternoon/early evening; maximum daily dose: 1.4 mg/kg/<b>day</b> or 100 mg/<b>day</b>, whichever is less. <b>Note:</b> Doses &gt;1.2 mg/kg/day have not been shown to provide additional benefit.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dosage adjustment in patients known to be CYP2D6 poor metabolizers</i>: Oral: Initial: 0.5 mg/kg/day; if tolerating therapy but inadequate response, may increase after a minimum of 4 weeks to 1.2 mg/kg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight &gt;70 kg: Oral: Initial: 40 mg once daily; increase after a minimum of 3 days to ~80 mg daily; may administer either once daily in the morning or in 2 evenly divided doses in morning and late afternoon/early evening. If optimal response has not been achieved after an additional 2 to 4 weeks of therapy, may increase dose up to a maximum daily dose: 100 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dosage adjustment in patients known to be CYP2D6 poor metabolizers</i>: Oral: Initial: 40 mg once daily; if tolerating therapy but inadequate response, may increase after a minimum of 4 weeks to 80 mg/day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51065107"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥6 years and Adolescents: No dosage adjustments are recommended.</p></div>
<div class="block dohp drugH1Div" id="F51065108"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥6 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate hepatic impairment: Administer 50% of normal dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe hepatic impairment: Administer 25% of normal dose.</p></div>
<div class="block arsc drugH1Div" id="F56188824"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Aggression/hostility</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine has been associated with <b>aggressive behavior </b>and <b>hostility</b> in pediatric patients, particularly with initiation. Overall, these events have occurred infrequently in trials with atomoxetine-treated children and adolescents, making it difficult to assess causality. Of note, some studies have not observed an increased risk. <b>Irritability</b>, which may be a precursor to hostility and aggression, has been observed more frequently with use. In addition, a case report of activation syndrome, described as an aggravation of preexisting attention-deficit/hyperactivity disorder (ADHD) symptoms in addition to new-onset aggression, irritability, disinhibition, and <b>insomnia</b>, has been reported in a child treated with a relatively high dose of atomoxetine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20040824','lexi-content-ref-33661138','lexi-content-ref-33780716','lexi-content-ref-16996485']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20040824','lexi-content-ref-33661138','lexi-content-ref-33780716','lexi-content-ref-16996485'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; aggressive behavior, by itself, is affected by many factors, such as genetics, environmental and psychosocial factors, cognition, hormones, and neurotransmitters. Atomoxetine, a potent inhibitor of presynaptic norepinephrine transporter may play a role in impulsive aggression through its actions on norepinephrine. It has also been suggested that increased irritability and aggression is due to incompletely treated ADHD and/or related to the condition of ADHD or other comorbidities and not related to pharmacologic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15342872','lexi-content-ref-16996485','lexi-content-ref-27290715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15342872','lexi-content-ref-16996485','lexi-content-ref-27290715'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; in one long-term safety and tolerability trial in children and adolescents with ADHD treated for ≥3 years, irritability and aggression occurred more frequently within the first month of treatment and then tended to subside over time; reports of hostility were observed sporadically over time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20040824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20040824'])">Ref</a></span>). One meta-analysis also observed a mean onset of 4 weeks following therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16996485']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16996485'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• ADHD, regardless of medication use, has been associated with aggressive behavior (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16996485']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16996485'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine, similar to the CNS stimulants used for attention-deficit/hyperactivity disorder (ADHD), has been associated with rare, but serious cardiovascular events, including sudden cardiac death (SCD), <b>acute myocardial infarction</b> (MI), or <b>cerebrovascular accident</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19528194','lexi-content-ref-21206410','lexi-content-ref-22682429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19528194','lexi-content-ref-21206410','lexi-content-ref-22682429'])">Ref</a></span>). However, a large retrospective cohort study in children and young adults (2 to 24 years) showed no evidence that current use of an ADHD medication (including atomoxetine) was associated with an increased risk of serious cardiovascular events compared to non-use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22043968']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22043968'])">Ref</a></span>). Other cohort studies in children and adolescents with ADHD have also failed to demonstrate an increased risk for SCD, MI, or stroke (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21576311']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21576311'])">Ref</a></span>). Consistent with these results, retrospective cohort studies in adults also found no evidence of an increased risk of MI, SCD, or stroke associated with current users of ADHD medication compared to non-users (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22161946','lexi-content-ref-19745645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22161946','lexi-content-ref-19745645'])">Ref</a></span>). Atomoxetine use has been shown to cause statistically significant increases in blood pressure and <b>increased</b>
<b>heart rate</b> (HR) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28236285','lexi-content-ref-15951476','lexi-content-ref-30127314','lexi-content-ref-23160939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28236285','lexi-content-ref-15951476','lexi-content-ref-30127314','lexi-content-ref-23160939'])">Ref</a></span>). Most pediatric patients experience a moderate increase in BP and/or HR, although in 8% to 12% of patients, a more significant increase occurred (ie, BP (≥15 to 20 mm Hg) and HR (≥20 bpm) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27290715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27290715'])">Ref</a></span>). In adult and pediatric patients, average increases in HR, systolic BP, and diastolic BP range from 3 to 10 bpm, 3 to 8 mm Hg and 2 to 14 mm Hg respectively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23362511','lexi-content-ref-30365404','lexi-content-ref-30531411','lexi-content-ref-12547466']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23362511','lexi-content-ref-30365404','lexi-content-ref-30531411','lexi-content-ref-12547466'])">Ref</a></span>). The manufacturer generally recommends against atomoxetine use in children and adolescents with serious cardiac conditions (eg, structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities) and to consider avoiding use in adults with serious cardiac conditions. The American Academy of Pediatrics/American Heart Association (AAP/AHA) recommends that children undergo a cardiovascular evaluation prior to therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18698199','lexi-content-ref-18427125']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18698199','lexi-content-ref-18427125'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Has not been fully elucidated, but it has been suggested that atomoxetine, due to its selective inhibition of the presynaptic norepinephrine transporter, may increase blood pressure by way of increased norepinephrine in peripheral sympathetic neurons in select individuals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30127314','lexi-content-ref-17515448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30127314','lexi-content-ref-17515448'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; in studies, observed increases in HR and BP have occurred early in treatment (initial 12 to 24 weeks of treatment) but tend to stabilize over time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23362511','lexi-content-ref-23160939','lexi-content-ref-26329980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23362511','lexi-content-ref-23160939','lexi-content-ref-26329980'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Serious cardiovascular events:</p>
<p style="text-indent:-2em;margin-left:8em;">• Patients with serious structural heart disease, including cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems (manufacturer’s labeling) <b>Note:</b> ADHD is common in children with congenital structural cardiac disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33397689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33397689'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Increases in BP and/or HR:</p>
<p style="text-indent:-2em;margin-left:8em;">• Patients with central autonomic failure (may increase the risk of hypertension) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17515448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17515448'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• CYP2D6 poor metabolizers (potential risk factor; conflicting evidence exists) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23160939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23160939'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Preexisting hypertension</p>
<p style="text-indent:-2em;margin-left:8em;">• Preexisting tachycardia</p>
<p style="text-indent:-2em;margin-left:8em;">• Known cardiovascular disease</p>
<p style="text-indent:-2em;margin-left:8em;">• Known cerebrovascular disease</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Growth effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Growth retardation</b> (weight and height) have been observed in atomoxetine-treated pediatric patients during the early phase of treatment, but effects tend to be reversible or recover over the long term. Specifically, data suggests that decreases in body weight and/or height may occur in the first 2 years of atomoxetine treatment in pediatric patients; however, weight and growth recovers or starts to recover over 2 to 5 years of atomoxetine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27290715','lexi-content-ref-17979588','lexi-content-ref-15995021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27290715','lexi-content-ref-17979588','lexi-content-ref-15995021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown since growth is affected by many factors; however, it has been suggested that reductions in weight due to atomoxetine may be secondary to decreased appetite, resulting from the GI side effects associated with atomoxetine (eg, nausea, vomiting, upper abdominal pain); these GI side effects are typically highest in the first 1 to 3 months of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19445548','lexi-content-ref-27290715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19445548','lexi-content-ref-27290715'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: In one long-term, open-label study, atomoxetine-treated patients weighed less than expected compared to the population norm as early as 1 month following treatment initiation, with a maximum effect on weight observed at 15 months. This same trial observed an effect on height at 12 months with a maximum effect at 18 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17979588']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17979588'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric patients who are above average in height and weight before treatment have shown a more persistent decrease in growth in open-label studies (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17979588']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17979588'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hepatobiliary events, typically described as mild <b>increased serum alanine aminotransferase</b> and <b>increased serum aspartate aminotransferase</b> (without <b>jaundice</b> or other signs of liver failure) have been observed with atomoxetine use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33970028','lexi-content-ref-18176331']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33970028','lexi-content-ref-18176331'])">Ref</a></span>). There are also case reports of severe<b> hepatic injury</b>, including acute <b>hepatitis </b>and <b>acute hepatic failure</b> with one case of acute liver failure requiring emergency liver transplantation with atomoxetine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21663435','lexi-content-ref-21039766','lexi-content-ref-16769398','lexi-content-ref-17357382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21663435','lexi-content-ref-21039766','lexi-content-ref-16769398','lexi-content-ref-17357382'])">Ref</a></span>). Therapy discontinuation is warranted in any patient with signs of jaundice and/or laboratory evidence of liver injury.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown, but atomoxetine is metabolized primarily by CYP2D6 in the liver, therefore, metabolic idiosyncrasy due to a toxic intermediate or byproduct has been suggested as a potential mechanism. In some cases, drug-induced autoimmune hepatitis has also been suggested as a potential mechanism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21663435','lexi-content-ref-16769398']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21663435','lexi-content-ref-16769398'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; most reports of severe liver injury describe an onset of within 3 to 12 weeks following initiation, although it has been observed as early as 2 days after therapy or as late as 23 months following initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21663435','lexi-content-ref-21788760','lexi-content-ref-17357382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21663435','lexi-content-ref-21788760','lexi-content-ref-17357382'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Priapism</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Rare cases of <b>priapism</b> have been reported in pediatric patients treated with atomoxetine alone, and in pediatric patients taking atomoxetine and risperidone concomitantly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26199163','lexi-content-ref-24982313','lexi-content-ref-24577257','lexi-content-ref-32332473','lexi-content-ref-18562402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26199163','lexi-content-ref-24982313','lexi-content-ref-24577257','lexi-content-ref-32332473','lexi-content-ref-18562402'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Has not been elucidated; atomoxetine may cause priapism through central dopaminergic and peripheral noradrenergic actions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32332473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32332473'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; in one case report, onset occurred 2 weeks following atomoxetine initiation and the morning after a dose increase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32332473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32332473'])">Ref</a></span>) and in another case report, onset occurred several years after being maintained on a stable dose of atomoxetine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26199163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26199163'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Hematological dyscrasias (eg, sickle cell disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24982313','lexi-content-ref-24577257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24982313','lexi-content-ref-24577257'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Malignancies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24982313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24982313'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Perineal trauma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24982313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24982313'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Illicit substance use or alcohol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24577257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24577257'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant medications associated with priapism (psychotropic drugs such as trazodone, antihypertensive such as prazosin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24982313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24982313'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Psychosis/mania</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Treatment-emergent <b>psychosis</b> (predominately manifested as <b>auditory hallucination</b>), <b>mania</b>, or <b>hypomania</b> have been reported in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) receiving therapeutic doses of atomoxetine. In the vast majority of cases, these events have occurred in patients with no identifiable risk factor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23592075','lexi-content-ref-24494808','lexi-content-ref-15342872','lexi-content-ref-25020072','lexi-content-ref-19171629','lexi-content-ref-26037880','lexi-content-ref-19519271']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23592075','lexi-content-ref-24494808','lexi-content-ref-15342872','lexi-content-ref-25020072','lexi-content-ref-19171629','lexi-content-ref-26037880','lexi-content-ref-19519271'])">Ref</a></span>). Of note, bipolar disorder is highly comorbid with ADHD and there may be a potential risk for induction of manic symptoms with atomoxetine use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chang.2009','lexi-content-ref-28250566','lexi-content-ref-26037880']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chang.2009','lexi-content-ref-28250566','lexi-content-ref-26037880'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Norepinephrine hyperactivity has been suggested as a potential mechanism for inducing mania; atomoxetine increases norepinephrine concentration in the brain by its inhibition of the presynaptic norepinephrine transporter. Psychosis has been attributed to dopaminergic mechanisms; it has been suggested that atomoxetine may affect dopamine levels indirectly by its inhibition of the presynaptic norepinephrine transporter and it has also been suggested that due to structural similarities between norepinephrine and dopamine, the norepinephrine transporter may also reuptake dopamine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25020072']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25020072'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; data from an analysis of events in patients with ADHD treated with either atomoxetine or a stimulant, onset of psychiatric symptoms occurred within days or weeks of therapy initiation in ~2/3 of the postmarketing reports to Medwatch. In the remainder 1/3 of patients, onset began after months, except for a few cases where symptom onset occurred after years of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19171629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19171629'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">QTc prolongation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prolonged QT interval on ECG</b> has been reported postmarketing according to the manufacturer’s labeling and in a single published case report (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24233333']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24233333'])">Ref</a></span>). However, in clinical trials, there is no consistent evidence that atomoxetine results in clinically significant QTc prolongation at therapeutic doses in children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18793405','lexi-content-ref-22803597','lexi-content-ref-23160939','lexi-content-ref-21864451','lexi-content-ref-17698328','lexi-content-ref-12562062']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18793405','lexi-content-ref-22803597','lexi-content-ref-23160939','lexi-content-ref-21864451','lexi-content-ref-17698328','lexi-content-ref-12562062'])">Ref</a></span>). However, some literature has shown clinically significant QTc prolongation in certain populations. One placebo-controlled study in healthy CYP2D6 poor metabolizer adult males (atomoxetine is metabolized primarily by CYP2D6) did not observe a clinically significant change in QTc on day 7 compared with baseline, but did observe statistically significant increase in QTc observed with increasing atomoxetine concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22803597']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22803597'])">Ref</a></span>). In the setting of overdose, case reports suggest that atomoxetine may increase the QT interval at supratherapeutic doses; however, atomoxetine was combined with other agents known to have QT prolongation potential or inhibit CYP2D6 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15171487','lexi-content-ref-23160939','lexi-content-ref-15056530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15171487','lexi-content-ref-23160939','lexi-content-ref-15056530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> In overdose settings, atomoxetine has been shown to inhibit human ether-à-go-go-related gene (hERG) potassium channels, leading to prolongation of the QT interval (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19154426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19154426'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Atomoxetine specifically:</p>
<p style="text-indent:-2em;margin-left:8em;">• CYP2D6 poor metabolizers (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22803597','lexi-content-ref-23160939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22803597','lexi-content-ref-23160939'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27984328']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27984328'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher/supratherapeutic doses (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15171487','lexi-content-ref-23160939','lexi-content-ref-15056530','lexi-content-ref-19154426','lexi-content-ref-27984328']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15171487','lexi-content-ref-23160939','lexi-content-ref-15056530','lexi-content-ref-19154426','lexi-content-ref-27984328'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced QTc prolongation/torsades de pointes (TdP) (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure with a reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline QTc interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypokalemia, hypocalcemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Coadministration of multiple medications (≥2) that prolong the QT interval or increase drug interactions that increase serum drug concentrations of QTc prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Substance use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20210726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20210726'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal ideation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A meta-analysis observed a statically significant higher incidence of <b>suicidal ideation</b> with atomoxetine use in children and adolescent patients with attention-deficit/hyperactivity disorder (ADHD) compared to placebo. No deaths by suicide were reported in the clinical trials used in this meta-analysis although 1 patient attempted suicide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18176331']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18176331'])">Ref</a></span>). Other data or retrospective analysis have also observed an association with atomoxetine and suicidal ideation in pediatric patients with ADHD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25019647','lexi-content-ref-23777626','lexi-content-ref-25171160','lexi-content-ref-20040824','lexi-content-ref-19810780','lexi-content-ref-33780716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25019647','lexi-content-ref-23777626','lexi-content-ref-25171160','lexi-content-ref-20040824','lexi-content-ref-19810780','lexi-content-ref-33780716'])">Ref</a></span>). However, one observational study failed to find a statistically significant increased risk of suicidal ideation in atomoxetine-treated children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27810613']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27810613'])">Ref</a></span>) and one cohort study did not find an increased risk of suicidal events in pediatric patients treated with atomoxetine (to determine if increased risk of suicidal ideation observed in trials translated into an increased risk of suicide and suicide attempts). To date, there is no evidence for an increased risk of suicidal behavior or ideation in adults treated with atomoxetine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25019647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25019647'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; although it has been suggested that the relationship between ADHD and suicidal ideation (if one exists) may be related to underlying impulsivity and aggression and/or indirectly mediated by comorbidities such as depression rather than related to medication use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18176331']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18176331'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> In one meta-analysis, time to onset of the suicide-related events ranged from 9 to 32 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18176331']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18176331'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Patients with ADHD, regardless of medication use, are often considered to be at a higher risk for suicide compared to the general population and typically have an increased prevalence of many psychiatric comorbidities, such as depression, conduct disorder, and substance abuse, which are associated with an increased risk of suicide, regardless of medication use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18176331','lexi-content-ref-25019647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18176331','lexi-content-ref-25019647'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Children and adolescents with a history of serious suicidal attempt or depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21042924']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21042924'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F137771"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Percentages as reported in children, adolescents, and adults; some adverse reactions are increased in CYP2D6 poor or extensive metabolizers.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased diastolic blood pressure (≥15 mm Hg: 5% to 22%), increased heart rate (≥20 bpm: 10% to 23%) (Fay 2019)<span class="lexi-table-link-container"> (<a aria-label="Increased Heart Rate table link" class="lexi-table-link" data-table-id="lexi-content-increased-heart-rate" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-heart-rate')">table 1</a>)</span><span class="table-link" style="display:none;">Increased Heart Rate</span>, increased systolic blood pressure (≥15 mm Hg: 4% to 13%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Heart Rate" frame="border" id="lexi-content-increased-heart-rate" rules="all">
<caption style="text-align:center;">
<b>Atomoxetine: Adverse Reaction: Increased Heart Rate</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Atomoxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Heart rate ≥20 bpm; proportion of patients meeting threshold at any one time during clinical trial</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Heart rate ≥20 bpm; endpoint of trial</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Heart rate ≥20 bpm; proportion of patients meeting threshold at any one time during clinical trial</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Heart rate ≥20 bpm; endpoint of trial</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis (4% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (7% to 18%), constipation (1% to 11%), decreased appetite (15% to 23%), nausea (7% to 26%), vomiting (4% to 11%), xerostomia (17% to 35%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction (8% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness (8% to 11%), headache (19%), insomnia (1% to 19%)<span class="lexi-table-link-container"> (<a aria-label="Insomnia table link" class="lexi-table-link" data-table-id="lexi-content-insomnia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-insomnia')">table 2</a>)</span><span class="table-link" style="display:none;">Insomnia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Insomnia" frame="border" id="lexi-content-insomnia" rules="all">
<caption style="text-align:center;">
<b>Atomoxetine: Adverse Reaction: Insomnia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Atomoxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Atomoxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">CYP2D6 poor metabolizers</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">CYP2D6 extensive metabolizers</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Middle insomnia; CYP2D6 poor metabolizers</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Middle insomnia; CYP2D6 extensive metabolizers</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">CYP2D6 poor metabolizers</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,697</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,560</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">CYP2D6 extensive metabolizers</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Middle insomnia; CYP2D6 poor metabolizers</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Middle insomnia; CYP2D6 extensive metabolizers</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Terminal insomnia; CYP2D6 poor metabolizers</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Terminal insomnia; CYP2D6 extensive metabolizers</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cold extremity (1% to 3%), orthostatic hypotension (≤2%), palpitations (3%), syncope (≤3%), tachycardia (≤2%)<span class="lexi-table-link-container"> (<a aria-label="Tachycardia table link" class="lexi-table-link" data-table-id="lexi-content-tachycardia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-tachycardia')">table 3</a>)</span><span class="table-link" style="display:none;">Tachycardia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Tachycardia" frame="border" id="lexi-content-tachycardia" rules="all">
<caption style="text-align:center;">
<b>Atomoxetine: Adverse Reaction: Tachycardia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Atomoxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Atomoxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,597</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">934</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">540</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">402</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Excoriation of skin (2% to 4%), skin rash (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (3%), hot flash (3%), increased thirst (2%), weight loss (2% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (3%), dyspepsia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (3%), dysuria (2%), ejaculatory disorder (2% to 6%), urinary hesitancy (6%), urinary retention (1% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (4%), chills (3%), depression (4% to 7%), dizziness (5% to 8%), emotional lability (1% to 2%), fatigue (6% to 10%), hostility (≤2%)<span class="lexi-table-link-container"> (<a aria-label="Hostility table link" class="lexi-table-link" data-table-id="lexi-content-hostility" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hostility')">table 4</a>)</span><span class="table-link" style="display:none;">Hostility</span>, irritability (5% to 6%)<span class="lexi-table-link-container"> (<a aria-label="Irritability table link" class="lexi-table-link" data-table-id="lexi-content-irritability" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-irritability')">table 5</a>)</span><span class="table-link" style="display:none;">Irritability</span>, jitteriness (2% to 5%), paresthesia (3%), sedated state (2% to 4%), sleep disturbance (3% to 7%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hostility" frame="border" id="lexi-content-hostility" rules="all">
<caption style="text-align:center;">
<b>Atomoxetine: Adverse Reaction: Hostility</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Atomoxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Atomoxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,308</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">806</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,697</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,560</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Irritability" frame="border" id="lexi-content-irritability" rules="all">
<caption style="text-align:center;">
<b>Atomoxetine: Adverse Reaction: Irritability</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Atomoxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Atomoxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,597</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">934</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,697</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,560</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (1% to 4%), conjunctivitis (1% to 3%), mydriasis (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Therapeutic response unexpected (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Nervous system: Delusion, hallucination, mania (Henderson 2004), psychotic symptoms (including psychosis and auditory hallucinations) (Mosholder 2009), seizure (Finsterer 2020), suicidal ideation (Bangs 2008)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing, sinus tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Menstrual disease, orgasm abnormal</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia, flatulence</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Pollakiuria, prostatitis, testicular pain, urinary urgency</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, anxiety, restlessness, sensation of cold</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia, muscle spasm</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (Seifi 2011), cardiomyopathy (takotsubo) (Yamaguchi 2014), cerebrovascular accident, prolonged QT interval on ECG (Yamaguchi 2014), Raynaud's disease (Gökçen 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Change in libido, growth retardation</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Pelvic pain (male), priapism (Armstrong 2015, Goetz 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure (can be acute hepatic failure) (Erdogan 2011), hepatic injury (severe) (Erdogan 2011, Lim 2006), hepatitis (Lim 2006), hepatotoxicity (Lim 2006), increased serum alanine aminotransferase (Abrams 2021, Bangs 2008), increased serum aspartate aminotransferase (Abrams 2021, Bangs 2008), jaundice (Lim 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal sensory symptoms, aggressive behavior (Donnelly 2009, Polzer 2007), akathisia (Yazici 2014), depressed mood, hypoesthesia, hypomania (Henderson 2004), impulsivity, lethargy, overstimulation (activation syndrome; Karakaya 2021), panic attack, tic disorder (Ledbetter 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Rhabdomyolysis</p></div>
<div class="block coi drugH1Div" id="F137784"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to atomoxetine or any component of the formulation; use with or within 14 days of MAO inhibitors; narrow-angle glaucoma; current or history of pheochromocytoma; severe cardiac or vascular disorders in which the condition would be expected to deteriorate with clinically important increases in blood pressure (eg, 15 to 20 mm Hg) or heart rate (eg, 20 beats/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:0em;margin-top:2em;">Canadian labeling: Additional contraindications (not in US labeling): Symptomatic cardiovascular diseases, moderate to severe hypertension; advanced arteriosclerosis; uncontrolled hyperthyroidism</p></div>
<div class="block war drugH1Div" id="F137769"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Attention-deficit/hyperactivity disorder and comorbidities: Randomized, controlled trials have demonstrated that atomoxetine does not worsen anxiety in patients with existing anxiety disorders or tics related to Tourette disorder.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bipolar disorder: Patients with bipolar disorder or risk factors for bipolar disorder (eg, family history of mania and depression) may be at increased risk for mania or mixed episodes during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustments necessary in moderate and severe hepatic insufficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary retention: Use with caution in patients with a history of urinary retention or bladder outlet obstruction; may cause urinary retention/hesitancy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CYP2D6 poor metabolizers: When atomoxetine is being used to treat attention-deficit/hyperactivity disorder, dosage adjustments are recommended in CYP2D6 poor metabolizers; these patients have increased exposure to atomoxetine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Attention-deficit/hyperactivity disorder treatment: Appropriate use: Recommended to be used as part of a comprehensive treatment program for attention deficit disorders.</p></div>
<div class="block foc drugH1Div" id="F137779"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Strattera: 10 mg, 18 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Strattera: 25 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Strattera: 40 mg, 60 mg, 80 mg [contains corn starch, fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Strattera: 100 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg</p></div>
<div class="block geq drugH1Div" id="F137765"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F137785"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Atomoxetine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $14.22 - $14.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">18 mg (per each): $14.22 - $14.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $14.22 - $14.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $7.60 - $15.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $15.45 - $15.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $16.67 - $16.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $16.67 - $16.69</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Strattera Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $15.82</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">18 mg (per each): $15.82</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $15.82</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $17.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $17.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $18.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $18.54</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866006"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Strattera: 10 mg [DSC], 18 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Strattera: 25 mg [DSC], 40 mg [DSC], 60 mg, 80 mg, 100 mg [DSC] [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg</p></div>
<div class="block adm drugH1Div" id="F137781"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to food. Do not crush, chew, or open capsule; swallow whole. <b>Note:</b> Atomoxetine is an ocular irritant; if capsule is opened inadvertently and contents come into contact with eye, flush eye immediately with water and obtain medical advice; wash hands and any potentially contaminated surface as soon as possible.</p></div>
<div class="block admp drugH1Div" id="F52612274"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to food. Do not crush, chew, or open capsule; swallow whole with water or other liquids. <b>Note:</b> Atomoxetine is an ocular irritant; if capsule is opened inadvertently and contents come into contact with eye, flush eye immediately with water and obtain medical advice; wash hands and any potentially contaminated surface as soon as possible.</p></div>
<div class="block meg drugH1Div" id="F7874384"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F021411s048lbl.pdf%23page%3D19&amp;token=xmRnWso5J6Ux7Th9hrk1ljbfDYYfQHjzt9ykptNMt75l4cXpdOjcoLvWjKyBuNRZvXCkpjzhhagpbhOE4e9Ctg%2FVdQ7kNfL5fDzs2ImgpiLPNCY6spIzlk15UvHnYfSR&amp;TOPIC_ID=8787" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021411s048lbl.pdf#page=19</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F137780"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Attention-deficit/hyperactivity disorder:</b> Treatment of attention-deficit/hyperactivity disorder (ADHD).</p></div>
<div class="block off-label drugH1Div" id="F56594297"><span class="drugH1">Use: Off-Label: Adult</span><p>Orthostatic hypotension, neurogenic</p></div>
<div class="block mst drugH1Div" id="F8002173"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Atomoxetine may be confused with atorvastatin.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F137810"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (minor), CYP2D6 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F137773"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: Atomoxetine may enhance the tachycardic effect of Beta2-Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Atomoxetine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Atomoxetine. Management: Initiate atomoxetine at a reduced dose (patients who weigh up to 70 kg: 0.5 mg/kg/day; adults or patients who weigh 70 kg or more: 40 mg/day) in patients receiving a strong CYP2D6 inhibitor. Increase to usual target dose after 4 weeks if needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Selective Norepinephrine Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the neurotoxic (central) effect of Atomoxetine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Selective Norepinephrine Reuptake Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: Atomoxetine may enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49095567"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Appropriate contraception is recommended for sexually active women of childbearing potential (Heiligenstein 2003). An agent other than atomoxetine is preferred for the treatment of attention-deficit/hyperactivity disorder (ADHD) in women planning a pregnancy (Larsen 2015).</p></div>
<div class="block pri drugH1Div" id="F137786"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">In comparison to other agents used for the treatment of attention-deficit/hyperactivity disorder (ADHD), information related to atomoxetine use in pregnancy is limited (Bro 2015; Haervig 2014; Heiligenstein 2003; Ornoy 2018).</p>
<p style="text-indent:0em;margin-top:2em;">If medication is needed for the treatment of ADHD during pregnancy, an agent other than atomoxetine is preferred. Consider discontinuing or changing treatment in patients who become pregnant during atomoxetine therapy (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to atomoxetine is ongoing. Health care providers are encouraged to enroll patients exposed to atomoxetine during pregnancy in the National Pregnancy Registry for ADHD medications at 1-866-961-2388.</p></div>
<div class="block brc drugH1Div" id="F20547477"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if atomoxetine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. An agent other than atomoxetine is preferred for the treatment of attention-deficit/hyperactivity disorder (ADHD) in women who are breastfeeding (Larsen 2015).</p></div>
<div class="block mop drugH1Div" id="F137777"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Liver enzymes (upon signs/symptoms of liver dysfunction and for several weeks after discontinuation for liver dysfunction). Cardiac evaluation should be completed at baseline (medical history and family history of sudden death or ventricular arrhythmia, physical exam to assess for cardiac disease; further evaluation such as ECG if findings suggest cardiac disease) and on any patient who develops exertional chest pain, unexplained syncope, and any symptom of cardiac disease during treatment. Monitor BP and heart rate (baseline, following dose increases and periodically during treatment); growth (weight and height) and appetite in children; weight in adults; sleep and behavioral changes. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial few months of therapy or during periods of dosage adjustments (increases or decreases). Screen for risk factors for bipolar disorder (eg, personal or family history of bipolar disorder, mania, hypomania and depression) prior to therapy initiation; monitor for signs/symptoms of mania/hypomania during therapy.</p></div>
<div class="block rer drugH1Div" id="F54201203"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Timing of serum samples:</i> In normal, intermediate, and ultrarapid CYP26 metabolizers or in patients with unknown CYP2D6 metabolizer status, draw peak plasma concentrations 1 to 2 hours after dose. In intermediate CYP2D6 metabolizers, consider drawing peak plasma concentrations 2 to 4 hours after dose in patients with lower enzyme activity or if the *10 allele is present. For poor CYP2D6 metabolizers, draw peak plasma concentrations 4 hours after dose (Brown 2019; Hiemke 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Therapeutic reference range:</i> 200 to 1,000 ng/mL (782 to 3,910 nmol/L) (Hiemke 2018). <b>Note:</b> There is no clear correlation with therapeutic levels and efficacy or tolerability; base dosing on therapeutic response as opposed to serum concentrations (Hazell 2009; Michelson 2007). However, therapeutic drug levels may be useful in patients with CYP2D6 polymorphisms that have a poor treatment response (Brown 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Laboratory alert level:</i> 2,000 ng/mL (7,820 nmol/L) (Hiemke 2018).</p></div>
<div class="block pha drugH1Div" id="F137768"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Selectively inhibits the reuptake of norepinephrine (Ki 4.5 nM) with little to no activity at the other neuronal reuptake pumps or receptor sites.</p></div>
<div class="block phk drugH1Div" id="F137783"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>The pharmacokinetics in pediatric patients ≥6 years of age have been shown to be similar to those of adult patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of action: Up to 24 hours (Jain 2017)</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: IV: 0.85 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 98%, primarily albumin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, via CYP2D6 and CYP2C19; forms metabolites (4-hydroxyatomoxetine, active, equipotent to atomoxetine; N-desmethylatomoxetine, limited activity); <b>Note:</b> CYP2D6 poor metabolizers have atomoxetine AUCs that are ~10-fold higher and peak concentrations that are ~fivefold greater than extensive metabolizers; 4-hyroxyatomoxetine plasma concentrations are very low (extensive metabolizers: 1% of atomoxetine concentrations; poor metabolizers: 0.1% of atomoxetine concentrations</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 63% in extensive metabolizers; 94% in poor metabolizers</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Atomoxetine: 5 hours (up to 24 hours in poor metabolizers); Active metabolites: 4-hydroxyatomoxetine: 6-8 hours; N-desmethylatomoxetine: 6-8 hours (34-40 hours in poor metabolizers)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 1-2 hours; delayed 3 hours by high-fat meal</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (80%, as conjugated 4-hydroxy metabolite; &lt;3% is excreted unchanged); feces (17%)</p></div>
<div class="block phksp drugH1Div" id="F51220453"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Extensive metabolizers with ESRD had higher systemic exposure (approximately a 65% increase), but there was no difference when exposure was corrected for mg/kg dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC is increased in extensive metabolizers with moderate or severe hepatic impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F855137"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Strattera</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Recit | Strattera</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Atofab | Atomoxetin sandoz | Atomoxetin stada | Strattera</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo atomoxetine | Atomerra | Atomoxetine amneal | Atomoxetine sandoz | Strattera</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Attentin | Suev</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Strattera</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Atofab | Strattera</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Atomoxetin mepha | Strattera</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Abretia | Deaten | Strattera</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Strattera</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Abretia | Attentho | Strattera | Tomoxet | Tonebec</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Atofab | Atominex | Atomoxetin actavis | Atomoxetin glenmark | Atomoxetin mylan | Atomoxetin sandoz | Atomoxetine accord | Aurodehade | Bitinex | Strattera</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Atomoxe 1a pharma | Atomoxetin | Atomoxetin accord | Atomoxetin al | Atomoxetin fairmed | Atomoxetin neuraxpharm | Atomoxetin zentiva | Strattera</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Strattera</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Atominex | Strattera</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Atomafutix | Atomoxapex | Atomoxetine | Attensera | Kemoxetin | Strattera</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Atamax | Atomoxetina aurovitas | Atomoxetina cinfa | Dezaprex | Strattera</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Atomoxetin orion | Atomoxetine accord | Atomoxetine stada | Strattera</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Atomaid | Atomoxetine | Atomoxetine glenmark | Atomoxetine macleods | Atomoxetine neuraxpharm | Strattera</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Strattera</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo atomoxetine | Strattera</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Atomoxetin sandoz | Bitinex | Strattera</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Xenocy</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Atomoxetine accord</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Strattera</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Atokem | Attentrol | Tomoxetin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Strattera</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Amotex | Strattera</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Atomoxetine | Atomoxetine amel | Atomoxetine pfizer | Strattera</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Strattera</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Artlex | Atocera | Atomotera | Atomoxetine | Atomoxin | Atosera | Domotine | Strattera | Wi atomoxetin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Strattera</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Pms atomoxetine | Strattera</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Strattera</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Strattera</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Atomoxetin beta | Atomoxetin neuraxpharm | Atomoxetin puren | Atomoxetine accord | Atomoxetine sandoz | Atomoxetine stada | Atomoxetine zentiva | Strattera</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Strattera</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Aittaret | Atomoxetina | Exotrima | Focusfar | Initome | Masennus | Moxazyd | Nodaten | Piquefu | Strattera | Yasag</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Strattera</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Atomoxetine accord | Atomoxetine glenmark | Atomoxetine hcl aurobindo | Atomoxetine teva | Strattera</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Atomoxetine medical valley | Atomoxetine sandoz | Atomoxetine teva | Strattera</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo atomoxetine | Strattera</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Abretia | Strattera</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Strattera</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Ads | Atohype | Doqaz | Etonis | Moxetin | Oxtin | Strattera</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Atofab | Atomoxetine NeuroPharma | Auroxetyn | Konaten | Strattera</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Atomoxetine | Strattera</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Atomoxetina generis | Atomoxetina pentafarma | Atomoxetina ratiopharm | Strattera</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Abretia</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Strattera</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Atofab | Atomoxetina accord | Atomoxetina actavis | Atomoxetina aurobindo | Atomoxetina zentiva | Bitinex</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dismaxin | Strattera</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Axepta | Strattera</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Atomoxetin actavis | Atomoxetin Ebb | Atomoxetin glenmark | Atomoxetin medical valley | Atomoxetin mylan | Atomoxetin orion | Atomoxetine accord | Atomoxetine sandoz | Atomoxetine stada | Strattera</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Strattera</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Strattera</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Atofab | Atominex | Atomoxetin mylan | Atomoxetine actavis | Atomoxetine sandoz | Strattera</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Strattera</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Strattera</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Atominex | Attex | Fixatom | Setinox | Strattera</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Apo atomoxetine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Monsetin | Pms atomoxetine | Strattera</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Abretia | Recit</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Abretia | Atomoxetina | Strattera</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Atastrat | Attencit | Attentra | Attentus | Inir | Stratex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33970028">
<a name="33970028"></a>Abrams M, Hasan S, Mehta A. <i>Letter to the Editor:</i> Liver Enzyme Elevation from Atomoxetine Use-A Case Report. <i>J Child Adolesc Psychopharmacol</i>. 2021;31(4):322-323. doi:10.1089/cap.2021.0014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/33970028/pubmed" id="33970028" target="_blank">33970028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20210726">
<a name="20210726"></a>Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. <i>Curr Drug Saf</i>. 2010;5(1):97-104. doi:10.2174/157488610789869265<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/20210726/pubmed" id="20210726" target="_blank">20210726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18698199">
<a name="18698199"></a>American Academy of Pediatrics/American Heart Association. American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008. <i>J Dev Behav Pediatr</i>. 2008;29(4):335.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/18698199/pubmed" id="18698199" target="_blank">18698199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23362511">
<a name="23362511"></a>Arcieri R, Germinario SEA, Bonati M, et al; Italian Attention-Deficit/Hyperactivity Disorder Regional Reference Centers. Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. <i>J Child Adolesc Psychopharmacol</i>. 2012;22(6):423-431. doi:10.1089/cap.2012.0014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/23362511/pubmed" id="23362511" target="_blank">23362511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26199163">
<a name="26199163"></a>Armstrong WR, Grimsby GM, Jacobs MA. Pediatric priapism secondary to psychotherapeutic medications. <i>Urology</i>. 2015;86(2):376-378. doi:10.1016/j.urology.2015.05.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/26199163/pubmed" id="26199163" target="_blank">26199163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23592075">
<a name="23592075"></a>Bahali K, Uneri OS, Ipek H. Atomoxetine-induced mania-like symptoms in an adolescent patient. <i>Actas Esp Psiquiatr</i>. 2013;41(2):137-138.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/23592075/pubmed" id="23592075" target="_blank">23592075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18176331">
<a name="18176331"></a>Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. <i>J Am Acad Child Adolesc Psychiatry</i>. 2008;47(2):209-218. doi:10.1097/chi.0b013e31815d88b2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/18176331/pubmed" id="18176331" target="_blank">18176331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25019647">
<a name="25019647"></a>Bangs ME, Wietecha LA, Wang S, Buchanan AS, Kelsey DK. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. <i>J Child Adolesc Psychopharmacol</i>. 2014;24(8):426-34. doi:10.1089/cap.2014.0005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/25019647/pubmed" id="25019647" target="_blank">25019647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15171487">
<a name="15171487"></a>Barker MJ, Benitez JG, Ternullo S, et al. Acute oxcarbazepine and atomoxetine overdose with quetiapine. <i>Vet Hum Toxicol</i>. 2004;46:130-132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/15171487/pubmed" id="15171487" target="_blank">15171487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brent.1">
<a name="Brent.1"></a>Brent D, Bukstein O, Solant MV. Attention deficit hyperactivity disorder in adults: Treatment overview. Post TW, ed. UpToDate. Waltham, MA: <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed January 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25657597">
<a name="25657597"></a>Bro SP, Kjaersgaard MI, Parner ET, et al. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. <i>Clin Epidemiol</i>. 2015;7:139-147. doi:10.2147/CLEP.S72906<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/25657597/pubmed" id="25657597" target="_blank">25657597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30801677">
<a name="30801677"></a>Brown JT, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy. <i>Clin Pharmacol Ther</i>. 2019;106(1):94-102. doi:10.1002/cpt.1409.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/30801677/pubmed" id="30801677" target="_blank">30801677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23777626">
<a name="23777626"></a>Bushe CJ, Savill NC. Suicide related events and attention deficit hyperactivity disorder treatments in children and adolescents: a meta-analysis of atomoxetine and methylphenidate comparator clinical trials. <i>Child Adolesc Psychiatry Ment Health</i>. 2013;7:19. doi:10.1186/1753-2000-7-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/23777626/pubmed" id="23777626" target="_blank">23777626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31856425">
<a name="31856425"></a>Byun JI, Kim DY, Moon J, et al. Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension. <i>Ann Clin Transl Neurol</i>. 2020;7(1):112-120. doi:10.1002/acn3.50968<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/31856425/pubmed" id="31856425" target="_blank">31856425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25171160">
<a name="25171160"></a>Capuano A, Scavone C, Rafaniello C, Arcieri R, Rossi F, Panei P. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation. <i>Expert Opin Drug Saf</i>. 2014;13(suppl 1):S69-S78. doi:10.1517/14740338.2014.941804<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/25171160/pubmed" id="25171160" target="_blank">25171160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chang.2009">
<a name="Chang.2009"></a>Chang K, Nayar D, Howe M, Rana M. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit=hyperactivity disorder in children and adolescents with bipolar I or II disorder. 2009;19:547-551. doi:10.1089=cap.2009.0030</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22043968">
<a name="22043968"></a>Cooper WO, Habel LA, Sox CM, et al. ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults. <i>N Engl J Med.</i> 2011;365(20):1896-1904. doi:10.1056/NEJMoa1110212<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/22043968/pubmed" id="22043968" target="_blank">22043968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27810613">
<a name="27810613"></a>Davies M, Coughtrie A, Layton D, Shakir SA. Use of atomoxetine and suicidal ideation in children and adolescents: Results of an observational cohort study within general practice in England. <i>Eur Psychiatry</i>. 2017;39:11-16. doi:10.1016/j.eurpsy.2016.06.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/27810613/pubmed" id="27810613" target="_blank">27810613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20040824">
<a name="20040824"></a>Donnelly C, Bangs M, Trzepacz P, et al. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. <i>J Am Acad Child Adolesc Psychiatry</i>. 2009;48(2):176-185. doi:10.1097/CHI.0b013e318193060e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/20040824/pubmed" id="20040824" target="_blank">20040824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24982313">
<a name="24982313"></a>Eiland LS, Bell EA, Erramouspe J. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children. <i>Ann Pharmacother</i>. 2014;48(10):1350-1355. doi:10.1177/1060028014541791.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/24982313/pubmed" id="24982313" target="_blank">24982313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21663435">
<a name="21663435"></a>Erdogan A, Ozcay F, Piskin E, et al. Idiosyncratic liver failure probably associated with atomoxetine: a case report. <i>J Child Adolesc Psychopharmacol</i>. 2011;21(3):295-297. doi:10.1089/cap.2010.0101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/21663435/pubmed" id="21663435" target="_blank">21663435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30365404">
<a name="30365404"></a>Fay TB, Alpert MA. Cardiovascular effects of drugs used to treat attention-deficit/hyperactivity disorder: Part 1: Epidemiology, pharmacology, and impact on hemodynamics and ventricular repolarization. <i>Cardiol Rev</i>. 2019;27(3):113-121. doi:10.1097/CRD.0000000000000233<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/30365404/pubmed" id="30365404" target="_blank">30365404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30531411">
<a name="30531411"></a>Fay TB, Alpert MA. Cardiovascular effects of drugs used to treat Attention-deficit/hyperactivity disorder Part 2: Impact on cardiovascular events and recommendations for evaluation and monitoring. <i>Cardiol Rev</i>. 2019;27(4):173-178. doi:10.1097/CRD.0000000000000234<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/30531411/pubmed" id="30531411" target="_blank">30531411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21039766">
<a name="21039766"></a>Ferrajolo C, Capuano A, Verhamme KM, et al. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in <i>VigiBase</i>. <i>Br J Clin Pharmacol</i>. 2010;70(5):721-728. doi:10.1111/j.1365-2125.2010.03754.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/21039766/pubmed" id="21039766" target="_blank">21039766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19445548">
<a name="19445548"></a>Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. <i>Paediatr Drugs</i>. 2009;11(3):203-226. doi:10.2165/00148581-200911030-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/19445548/pubmed" id="19445548" target="_blank">19445548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24577257">
<a name="24577257"></a>Goetz M, Surman CB. Prolonged penile erections associated with the use of atomoxetine and aripiprazole in an 11-year-old boy. <i>J Clin Psychopharmacol</i>. 2014;34(2):275-276. doi:10.1097/01.jcp.0000445185.90518.84<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/24577257/pubmed" id="24577257" target="_blank">24577257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33397689">
<a name="33397689"></a>Gonzalez VJ, Kimbro RT, Cutitta KE, et al. Mental health disorders in children with congenital heart disease. <i>Pediatrics</i>. 2021;147(2):e20201693. doi:10.1542/peds.2020-1693<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/33397689/pubmed" id="33397689" target="_blank">33397689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19528194">
<a name="19528194"></a>Gould MS, Walsh BT, Munfakh JL, et al. Sudden Death and Use of Stimulant Medications in Youths. <i>Am J Psychiatry.</i> 2009;166(9):992-1001. doi:10.1176/appi.ajp.2009.09040472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/19528194/pubmed" id="19528194" target="_blank">19528194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21042924">
<a name="21042924"></a>Graham J, Banaschewski T, Buitelaar J, et al; European Guidelines Group. European guidelines on managing adverse effects of medication for ADHD.<i> Eur Child Adolesc Psychiatry</i>. 2011;20(1):17-37. doi:10.1007/s00787-010-0140-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/21042924/pubmed" id="21042924" target="_blank">21042924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24494808">
<a name="24494808"></a>Guney E, Uneri OS. Atomoxetine-induced hypomania-like symptoms in a preadolescent patient. <i>J Child Adolesc Psychopharmacol</i>. 2014;24(9):530-531. doi:10.1089/cap.2013.0112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/24494808/pubmed" id="24494808" target="_blank">24494808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22161946">
<a name="22161946"></a>Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. <i>JAMA</i>. 2011;306(24):2673-2683. doi:10.1001/jama.2011.1830<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/22161946/pubmed" id="22161946" target="_blank">22161946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24590619">
<a name="24590619"></a>Haervig KB, Mortensen LH, Hansen AV, Strandberg-Larsen K. Use of ADHD medication during pregnancy from 1999 to 2010: a Danish register-based study. <i>Pharmacoepidemiol Drug Saf</i>. 2014;23(5):526-533. doi:10.1002/pds.3600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/24590619/pubmed" id="24590619" target="_blank">24590619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20234828">
<a name="20234828"></a>Hazell P, Becker K, Nikkanen EA, et al. Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. <i>Atten Defic Hyperact Disord</i>. 2009;1(2):201-210. doi:10.1007/s12402-009-0012-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/20234828/pubmed" id="20234828" target="_blank">20234828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Heiligenstein.1">
<a name="Heiligenstein.1"></a>Heiligenstein J, Michelson D, Wernicke J, et al. Atomoxetine and Pregnancy; Author Reply. <i>J Am Acad Child Adolesc Psychiatry. </i>2003;42(8):884-885.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15342872">
<a name="15342872"></a>Henderson TA, Hartman K. Aggression, mania, and hypomania induction associated with atomoxetine. <i>Pediatrics</i>. 2004;114(3):895-896. doi:10.1542/peds.2004-1140<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/15342872/pubmed" id="15342872" target="_blank">15342872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28236285">
<a name="28236285"></a>Hennissen L, Bakker MJ, Banaschewski T, et al; ADDUCE consortium. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: A systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. <i>CNS Drugs</i>. 2017;31(3):199-215. doi:10.1007/s40263-017-0410-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/28236285/pubmed" id="28236285" target="_blank">28236285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910830">
<a name="28910830"></a>Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. <i>Pharmacopsychiatry</i>. 2018;51(1-02):9-62. doi:10.1055/s-0043-116492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/28910830/pubmed" id="28910830" target="_blank">28910830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19745645">
<a name="19745645"></a>Holick CN, Turnbull BR, Jones ME, Chaudhry S, Bangs ME, Seeger JD. Atomoxetine and cerebrovascular outcomes in adults. <i>J Clin Psychopharmacol</i>. 2009;29(5):453-460. doi:10.1097/JCP.0b013e3181b2b828<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/19745645/pubmed" id="19745645" target="_blank">19745645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28906602">
<a name="28906602"></a>Jain R, Jain S, Montano B. Addressing diagnosis and treatment gaps in adults with attention-deficit/hyperactivity disorder. <i>Prim Care Companion CNS Disord. </i>2017;19(5). doi:10.4088/PCC.17nr02153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/28906602/pubmed" id="28906602" target="_blank">28906602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33661138">
<a name="33661138"></a>Karakaya SEK, Yektaş Ç, Tufan AE. Activation syndrome in a patient with attention-deficit/hyperactivity disorder treated with atomoxetine: A case report. <i>Clin Neuropharmacol</i>. 2021;44(3):101-103. doi:10.1097/WNF.0000000000000447<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/33661138/pubmed" id="33661138" target="_blank">33661138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32332473">
<a name="32332473"></a>Karayagmurlu A, Coskun M. Successful management of methylphenidate or atomoxetine-related priapism during attention-deficit hyperactivity disorder treatment. <i>J Clin Psychopharmacol</i>. 2020;40(3):314-315. doi:10.1097/JCP.0000000000001039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/32332473/pubmed" id="32332473" target="_blank">32332473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15951476">
<a name="15951476"></a>Kelly RP, Yeo KP, Teng CH, et al. Hemodynamic effects of acute administration of atomoxetine and methylphenidate. <i>J Clin Pharmacol</i>. 2005;45(7):851-855. doi:10.1177/0091270005276737<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/15951476/pubmed" id="15951476" target="_blank">15951476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18793405">
<a name="18793405"></a>Kratochvil CJ, Milton DR, Vaughan BS, Greenhill LL. Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy. <i>Child Adolesc Psychiatry Ment Health</i>. 2008;2(1):25. doi:10.1186/1753-2000-2-25<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/18793405/pubmed" id="18793405" target="_blank">18793405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28250566">
<a name="28250566"></a>Kumar V, Varambally S. Atomoxetine induced hypomania in a patient with bipolar disorder and adult attention deficit hyperactivity disorder. <i>Indian J Psychol Med</i>. 2017;39(1):89-91. doi:10.4103/0253-7176.198954<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/28250566/pubmed" id="28250566" target="_blank">28250566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al; Danish Psychiatric Society; Danish Society of Obstetrics and Gynecology; Danish Paediatric Society; Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28. doi:10.1111/acps.12479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30127314">
<a name="30127314"></a>Liang EF, Lim SZ, Tam WW, et al. The effect of methylphenidate and atomoxetine on heart rate and systolic blood pressure in young people and adults with attention-deficit hyperactivity disorder (ADHD): Systematic review, meta-analysis, and meta-regression. <i>Int J Environ Res Public Health</i>. 2018;15(8):1789. doi:10.3390/ijerph15081789<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/30127314/pubmed" id="30127314" target="_blank">30127314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16769398">
<a name="16769398"></a>Lim JR, Faught PR, Chalasani NP, Molleston JP. Severe liver injury after initiating therapy with atomoxetine in two children. <i>J Pediatr</i>. 2006;148(6):831-834. doi:10.1016/j.jpeds.2006.01.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/16769398/pubmed" id="16769398" target="_blank">16769398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25020072">
<a name="25020072"></a>Liu CC, Lan CC, Chen YS. Atomoxetine-induced mania with auditory hallucination in an 8-year-old boy with attention-deficit/hyperactivity disorder and tic disorder. <i>J Child Adolesc Psychopharmacol</i>. 2014;24(8):466-467. doi:10.1089/cap.2014.0038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/25020072/pubmed" id="25020072" target="_blank">25020072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22803597">
<a name="22803597"></a>Loghin C, Haber H, Beasley CM, et al. Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers. <i>Br J Clin Pharmacol</i>. 2013;75(2):538-549. doi:10.1111/j.1365-2125.2012.04382.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/22803597/pubmed" id="22803597" target="_blank">22803597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23160939">
<a name="23160939"></a>Martinez-Raga J, Knecht C, Szerman N, Martinez MI. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.<i> CNS Drugs</i>. 2013;27(1):15-30. doi:10.1007/s40263-012-0019-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/23160939/pubmed" id="23160939" target="_blank">23160939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19810780">
<a name="19810780"></a>McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. <i>Drug Saf</i>. 2009;32(11):1089-1096. doi:10.2165/11317630-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/19810780/pubmed" id="19810780" target="_blank">19810780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12547466">
<a name="12547466"></a>Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. <i>Biol Psychiatry</i>. 2003;53(2):112-120. doi:10.1016/s0006-3223(02)01671-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/12547466/pubmed" id="12547466" target="_blank">12547466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17242628">
<a name="17242628"></a>Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(2):242-251. doi:10.1097/01.chi.0000246056.83791.b6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/17242628/pubmed" id="17242628" target="_blank">17242628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21788760">
<a name="21788760"></a>Molleston JP, Fontana RJ, Lopez MJ, Kleiner DE, Gu J, Chalasani N; Drug-Induced Liver Injury Network. Characteristics of idiosyncratic drug-induced liver injury in children: Results from the DILIN prospective study. <i>J Pediatr Gastroenterol Nutr</i>. 2011;53(2):182-189. doi:10.1097/MPG.0b013e31821d6cfd<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/21788760/pubmed" id="21788760" target="_blank">21788760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19171629">
<a name="19171629"></a>Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. <i>Pediatrics</i>. 2009;123(2):611-616. doi:10.1542/peds.2008-0185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/19171629/pubmed" id="19171629" target="_blank">19171629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. https://www.nice.org.uk/guidance/ng87. March 14, 2018. Updated September 13, 2019. Accessed June 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22311903">
<a name="22311903"></a>Okamoto LE, Shibao C, Gamboa A, et al. Synergistic effect of norepinephrine transporter blockade and α-2 antagonism on blood pressure in autonomic failure. <i>Hypertension</i>. 2012;59(3):650-656. doi:10.1161/HYPERTENSIONAHA.111.184812<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/22311903/pubmed" id="22311903" target="_blank">22311903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30571543">
<a name="30571543"></a>Okamoto LE, Shibao CA, Gamboa A, et al. Synergistic pressor effect of atomoxetine and pyridostigmine in patients with neurogenic orthostatic hypotension. <i>Hypertension</i>. 2019;73(1):235-241. doi:10.1161/HYPERTENSIONAHA.118.11790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/30571543/pubmed" id="30571543" target="_blank">30571543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29411149">
<a name="29411149"></a>Ornoy A. Pharmacological treatment of attention deficit hyperactivity disorder during pregnancy and lactation. <i>Pharm Res</i>. 2018;35(3):46. doi:10.1007/s11095-017-2323-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/29411149/pubmed" id="29411149" target="_blank">29411149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31996627">
<a name="31996627"></a>Palma JA, Kaufmann H. Management of orthostatic hypotension. <i>Continuum (Minneap Minn)</i>. 2020;26(1):154-177. doi:10.1212/CON.0000000000000816<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/31996627/pubmed" id="31996627" target="_blank">31996627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Palma.2022">
<a name="Palma.2022"></a>Palma JA, Kaufmann H. Treatment of orthostatic and postprandial hypotension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed January 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33780716">
<a name="33780716"></a>Pang L, Sareen R. Retrospective analysis of adverse events associated with non-stimulant ADHD medications reported to the united states food and drug administration. <i>Psychiatry Res</i>. 2021;300:113861. doi:10.1016/j.psychres.2021.113861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/33780716/pubmed" id="33780716" target="_blank">33780716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26037880">
<a name="26037880"></a>Peruzzolo TL, Tramontina S, Rodrigues RB, Rohde LA, Zeni CP. Avoiding stimulants may not prevent manic switch: a case report with atomoxetine. <i>J Neuropsychiatry Clin Neurosci</i>. 2014;26(4):E30-E31. doi:10.1176/appi.neuropsych.13110328<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/26037880/pubmed" id="26037880" target="_blank">26037880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16996485">
<a name="16996485"></a>Polzer J, Bangs ME, Zhang S, et al. Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD. <i>Biol Psychiatry</i>. 2007;61(5):713-719. doi:10.1016/j.biopsych.2006.05.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/16996485/pubmed" id="16996485" target="_blank">16996485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31061208">
<a name="31061208"></a>Pringsheim T, Okun MS, Müller-Vahl K, et al. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. <i>Neurology</i>. 2019;92(19):896-906.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/31061208/pubmed" id="31061208" target="_blank">31061208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25185131">
<a name="25185131"></a>Ramirez CE, Okamoto LE, Arnold AC, et al. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. <i>Hypertension</i>. 2014;64(6):1235-1240. doi:10.1161/HYPERTENSIONAHA.114.04225<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/25185131/pubmed" id="25185131" target="_blank">25185131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27290715">
<a name="27290715"></a>Reed VA, Buitelaar JK, Anand E, et al. The safety of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of research. <i>CNS Drugs</i>. 2016;30(7):603-628. doi:10.1007/s40263-016-0349-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/27290715/pubmed" id="27290715" target="_blank">27290715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15056530">
<a name="15056530"></a>Sawant S, Daviss SR. Seizures and prolonged QTc with atomoxetine overdose [letter]. <i>Am J Psychiatry</i>. 2004;161:757. doi:10.1176/appi.ajp.161.4.757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/15056530/pubmed" id="15056530" target="_blank">15056530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21576311">
<a name="21576311"></a>Schelleman H, Bilker WB, Strom BL, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. <i>Pediatrics</i>. 2011;127(6):1102-1110. doi:10.1542/peds.2010-3371<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/21576311/pubmed" id="21576311" target="_blank">21576311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19154426">
<a name="19154426"></a>Scherer D, Hassel D, Bloehs R, et al. Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents. <i>Br J Pharmacol</i>. 2009;156:226-236. doi:10.1111/j.1476-5381.2008.00018.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/19154426/pubmed" id="19154426" target="_blank">19154426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21206410">
<a name="21206410"></a>Seifi A, Griffith H, Avestimehr S, Dib H. Atomoxetine-induced myocardial infarction. <i>South Med J</i>. 2011;104(2):153-154. doi:10.1097/SMJ.0b013e318205e575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/21206410/pubmed" id="21206410" target="_blank">21206410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21864451">
<a name="21864451"></a>Sert A, Gokcen C, Aypar E, Odabas D. Effects of atomoxetine on cardiovascular functions and on QT dispersion in children with attention deficit hyperactivity disorder. <i>Cardiol Young</i>. 2012;22(2):158-161. doi:10.1017/S1047951111001211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/21864451/pubmed" id="21864451" target="_blank">21864451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17515448">
<a name="17515448"></a>Shibao C, Raj SR, Gamboa A, et al. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. <i>Hypertension</i>. 2007;50(1):47-53. doi:10.1161/HYPERTENSIONAHA.107.089961<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/17515448/pubmed" id="17515448" target="_blank">17515448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17979588">
<a name="17979588"></a>Spencer TJ, Kratochvil CJ, Sangal RB, et al. Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment. <i>J Child Adolesc Psychopharmacol</i>. 2007;17(5):689-700. doi:10.1089/cap.2006.0100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/17979588/pubmed" id="17979588" target="_blank">17979588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15995021">
<a name="15995021"></a>Spencer TJ, Newcorn JH, Kratochvil CJ, Ruff D, Michelson D, Biederman J. Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. <i>Pediatrics</i>. 2005;116(1):e74-e80. doi:10.1542/peds.2004-0624<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/15995021/pubmed" id="15995021" target="_blank">15995021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17357382">
<a name="17357382"></a>Stojanovski SD, Casavant MJ, Mousa HM, Baker P, Nahata MC. Atomoxetine-induced hepatitis in a child. <i>Clin Toxicol (Phila)</i>. 2007;45(1):51-55. doi:10.1080/15563650600795644<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/17357382/pubmed" id="17357382" target="_blank">17357382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Strattera.2020.02">
<a name="Strattera.2020.02"></a>Strattera (atomoxetine) [prescribing information]. Indianapolis, IN: Lilly USA LLC; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Strattera.2015.10">
<a name="Strattera.2015.10"></a>Strattera (atomoxetine) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; October 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27984328">
<a name="27984328"></a>Suzuki Y, Tajiri M, Sugimoto A, et al. Sex differences in the effect of atomoxetine on the QT interval in adult patients with attention-deficit hyperactivity disorder. <i>J Clin Psychopharmacol</i>. 2017;37(1):27-31. doi:10.1097/JCP.0000000000000630<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/27984328/pubmed" id="27984328" target="_blank">27984328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19519271">
<a name="19519271"></a>Tang CS, Chou WJ, Cheng AT. Atomoxetine hydrochloride-associated transient psychosis in an adolescent with attention-deficit/hyperactivity disorder and mild mental retardation. <i>J Child Adolesc Psychopharmacol</i>. 2009;19(3):319-320. doi:10.1089/cap.2008.073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/19519271/pubmed" id="19519271" target="_blank">19519271</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: A scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152. Erratum in: <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(6):e57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24803473">
<a name="24803473"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(3):381-390. doi:10.1161/CIRCOUTCOMES.113.000651. Erratum in: <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(6):981.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/24803473/pubmed" id="24803473" target="_blank">24803473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17698328">
<a name="17698328"></a>Trzepacz PT, Williams DW, Feldman PD, Wrishko RE, Witcher JW, Buitelaar JK. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. <i>Eur Neuropsychopharmacol</i>. 2008;18(2):79-86. doi:10.1016/j.euroneuro.2007.06.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/17698328/pubmed" id="17698328" target="_blank">17698328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26329980">
<a name="26329980"></a>Upadhyaya H, Tanaka Y, Lipsius S, et al. Time-to-onset and -resolution of adverse events before/after atomoxetine discontinuation in adult patients with ADHD. <i>Postgrad Med</i>. 2015;127(7):677-685. doi:10.1080/00325481.2015.1083394<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/26329980/pubmed" id="26329980" target="_blank">26329980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18427125">
<a name="18427125"></a>Vetter VL, Elia J, Erickson CH, et al; American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. <i>Circulation</i>. 2008;117(18):2407-2423. doi:10.1161/CIRCULATIONAHA.107.189473<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/18427125/pubmed" id="18427125" target="_blank">18427125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18562402">
<a name="18562402"></a>Wadoo O, Chalhoub N. Risperidone-induced sexual dysfunction in a prepubertal child - a case report. <i>J Psychopharmacol</i>. 2009;23(6):727-728. doi:10.1177/0269881108091593<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/18562402/pubmed" id="18562402" target="_blank">18562402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12562062">
<a name="12562062"></a>Wernicke JF, Kratochvil CJ. Safety Profile of Atomoxetine in the Treatment of Children and Adolescents With ADHD. <i>J Clin Psychiatry. </i>2002;63(suppl 12):50-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/12562062/pubmed" id="12562062" target="_blank">12562062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22682429">
<a name="22682429"></a>Westover AN, Halm EA. Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review. <i>BMC Cardiovasc Disord</i>. 2012;12:41. doi:10.1186/1471-2261-12-41<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/22682429/pubmed" id="22682429" target="_blank">22682429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31570648">
<a name="31570648"></a>Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. <i>Pediatrics</i>. 2019;144(4):e20192528.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/31570648/pubmed" id="31570648" target="_blank">31570648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24233333">
<a name="24233333"></a>Yamaguchi H, Nagumo K, Nakashima T, Kinugawa Y, Kumaki S. Life-threatening QT prolongation in a boy with attention-deficit/hyperactivity disorder on atomoxetine. <i>Eur J Pediatr</i>. 2014;173(12):1631-1634. doi:10.1007/s00431-013-2206-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atomoxetine-drug-information/abstract-text/24233333/pubmed" id="24233333" target="_blank">24233333</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8787 Version 322.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
